Logo image of CAMP

CAMP4 THERAPEUTICS CORP (CAMP) Stock Price, Quote, News and Overview

NASDAQ:CAMP - Nasdaq - US13463J1016 - Currency: USD

4.81  -0.02 (-0.41%)

After market: 4.81 0 (0%)

CAMP Quote, Performance and Key Statistics

CAMP4 THERAPEUTICS CORP

NASDAQ:CAMP (2/21/2025, 8:05:06 PM)

After market: 4.81 0 (0%)

4.81

-0.02 (-0.41%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High12.3
52 Week Low0.39
Market Cap96.97M
Shares20.16M
Float12.12M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO10-11 2024-10-11


CAMP short term performance overview.The bars show the price performance of CAMP in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 30 40

CAMP long term performance overview.The bars show the price performance of CAMP in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of CAMP is 4.81 USD. In the past month the price decreased by -11.58%. In the past year, price decreased by -20.93%.

CAMP4 THERAPEUTICS CORP / CAMP Daily stock chart

CAMP Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About CAMP

Company Profile

CAMP4 Therapeutics Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 58 full-time employees. The company went IPO on 2024-10-11. CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases. The company is leveraging its RAP Platform to advance a pipeline of programs initially focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.

Company Info

CAMP4 THERAPEUTICS CORP

One Kendall Square, Bldg 1400 West 3rd Floor

Cambridge MASSACHUSETTS 92618 US

CEO: Jeffery Gardner

Employees: 58

Company Website: https://www.camp4tx.com/

Phone: 16176518867

CAMP4 THERAPEUTICS CORP / CAMP FAQ

What is the stock price of CAMP4 THERAPEUTICS CORP today?

The current stock price of CAMP is 4.81 USD. The price decreased by -0.41% in the last trading session.


What is the ticker symbol for CAMP4 THERAPEUTICS CORP stock?

The exchange symbol of CAMP4 THERAPEUTICS CORP is CAMP and it is listed on the Nasdaq exchange.


On which exchange is CAMP stock listed?

CAMP stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CAMP4 THERAPEUTICS CORP stock?

10 analysts have analysed CAMP and the average price target is 19.38 USD. This implies a price increase of 302.91% is expected in the next year compared to the current price of 4.81. Check the CAMP4 THERAPEUTICS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CAMP4 THERAPEUTICS CORP worth?

CAMP4 THERAPEUTICS CORP (CAMP) has a market capitalization of 96.97M USD. This makes CAMP a Micro Cap stock.


How many employees does CAMP4 THERAPEUTICS CORP have?

CAMP4 THERAPEUTICS CORP (CAMP) currently has 58 employees.


What are the support and resistance levels for CAMP4 THERAPEUTICS CORP (CAMP) stock?

CAMP4 THERAPEUTICS CORP (CAMP) has a support level at 4.78 and a resistance level at 5.11. Check the full technical report for a detailed analysis of CAMP support and resistance levels.


Is CAMP4 THERAPEUTICS CORP (CAMP) expected to grow?

The Revenue of CAMP4 THERAPEUTICS CORP (CAMP) is expected to decline by -92.93% in the next year. Check the estimates tab for more information on the CAMP EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CAMP4 THERAPEUTICS CORP (CAMP) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CAMP4 THERAPEUTICS CORP (CAMP) stock pay dividends?

CAMP does not pay a dividend.


What is the Price/Earnings (PE) ratio of CAMP4 THERAPEUTICS CORP (CAMP)?

CAMP4 THERAPEUTICS CORP (CAMP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-22.81).


What is the Short Interest ratio of CAMP4 THERAPEUTICS CORP (CAMP) stock?

The outstanding short interest for CAMP4 THERAPEUTICS CORP (CAMP) is 2.35% of its float. Check the ownership tab for more information on the CAMP short interest.


CAMP Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

CAMP Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to CAMP. CAMP has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CAMP Financial Highlights

Over the last trailing twelve months CAMP reported a non-GAAP Earnings per Share(EPS) of -22.81. The EPS decreased by -17446.15% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -36.04%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-1647.16%
Sales Q2Q%-100%
EPS 1Y (TTM)-17446.15%
Revenue 1Y (TTM)-7.05%

CAMP Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to CAMP. The Buy consensus is the average rating of analysts ratings from 10 analysts.

For the next year, analysts expect an EPS growth of -591.99% and a revenue growth -92.93% for CAMP


Ownership
Inst Owners50.65%
Ins Owners3.6%
Short Float %2.35%
Short Ratio2.64
Analysts
Analysts86
Price Target19.38 (302.91%)
EPS Next Y-591.99%
Revenue Next Year-92.93%